Compass Therapeutics (CMPX) Operating Leases (2021 - 2026)

Compass Therapeutics (CMPX) has 6 years of Operating Leases data on file, last reported at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 34.22% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (up 34.22% YoY), and the FY2025 full-year result was $8.8 million, up 40.23% from the prior year.
• Operating Leases retreated to $8.4 million in Q1 2026, from $8.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.8 million in Q3 2025 to a low of $536000.0 in Q4 2023.
• A 5-year average of $4.7 million and a median of $3.0 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 70.84% in 2023 and soared 1074.63% in 2024, its largest moves.
• Tracing CMPX's Operating Leases over 5 years: stood at $1.8 million in 2022, then slumped by 70.84% to $536000.0 in 2023, then soared by 1074.63% to $6.3 million in 2024, then jumped by 40.23% to $8.8 million in 2025, then fell by 4.66% to $8.4 million in 2026.
• Business Quant data shows CMPX's Operating Leases at $8.4 million in Q1 2026, $8.8 million in Q4 2025, and $9.8 million in Q3 2025.